Known targets — ChEMBL curated mechanism
DRD2DRD3DRD4GNRHRHRH1HTR2AHTR2CSLC6A2SLC6A4SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Pamoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.51 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.51 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.51 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.51 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.51 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.51 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pamoic Acid SCHEMBL21834068 | 0.95 | SLC6A4 (0.56) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Pamoic Acid SCHEMBL41090 | 0.95 | SLC6A4 (0.56) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Pamoic Acid SCHEMBL517584 | 0.89 | SLC6A4 (0.47) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Pamoic Acid SCHEMBL16222836 | 0.89 | SLC6A4 (0.63) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Imipramine SCHEMBL518586 | 0.86 | KMT2A (0.44) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Imipramine SCHEMBL2098515 | 0.80 | LMNA (0.62) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Pamoic Acid SCHEMBL15533092 | 0.80 | SLC6A4 (0.48) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Pamoic Acid SCHEMBL517883 | 0.80 | POLB (0.81) | MAPTCYP2D6ALDH1A1POLBGPR35 | |
| SCHEMBL5608291 | 0.78 | SLC6A4 (0.47) | SLC6A4MAPTHRH1LMNAADORA3 | |
| Imipramine SCHEMBL4283852 | 0.77 | SLC6A4 (0.71) | SLC6A4MAPTHRH1LMNAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9226925-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-8980880-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8957067-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8940729-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8916587-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-8912217-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8716278-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716337-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8653065-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653106-B2 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8586575-B1 | Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder | PISGAH LABORATORIES, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | PISGAH LABORATORIES, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028960-A1 | ABUSE DETERRENT AND ANTI-DOSE DUMPING PHARMACEUTICAL SALTS USEFUL FOR THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER | COMT, SLC6A3, SLC6A2 | SLC6A4 4/4885HRH1 160/4885DRD2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.